Cargando…

Patient specific real-time PCR in precision medicine – Validation of IG/TR based MRD assessment in lymphoid leukemia

Detection of patient- and tumor-specific clonally rearranged immune receptor genes using real-time quantitative (RQ)-PCR is an accepted method in the field of precision medicine for hematologic malignancies. As individual primers are needed for each patient and leukemic clone, establishing performan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schilhabel, Anke, Szczepanowski, Monika, van Gastel-Mol, Ellen J., Schillalies, Janina, Ray, Jill, Kim, Doris, Nováková, Michaela, Dombrink, Isabel, van der Velden, Vincent H. J., Boettcher, Sebastian, Brüggemann, Monika, Kneba, Michael, van Dongen, Jacques J. M., Langerak, Anton W., Ritgen, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885152/ https://www.ncbi.nlm.nih.gov/pubmed/36727082 http://dx.doi.org/10.3389/fonc.2022.1111209

Ejemplares similares

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

The New EU Regulation on In Vitro Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories
por: Lubbers, Bart R., et al.
Publicado: (2021)

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis
por: Schilhabel, Anke, et al.
Publicado: (2022)

Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study
por: van der Velden, Vincent H. J., et al.
Publicado: (2021)

IGH Rearrangement Evolution in Adult KMT2A-rearranged B-cell Precursor ALL: Implications for Cell-of-origin and MRD Monitoring
por: Darzentas, Franziska, et al.
Publicado: (2022)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion
por: Venn, N C, et al.
Publicado: (2012)

pmTR database: population matched (pm) germline allelic variants of T-cell receptor (TR) loci
por: Dekker, Julian, et al.
Publicado: (2022)

Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force
por: Dombrink, Isabel, et al.
Publicado: (2022)

Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities
por: Lubbers, Bart R., et al.
Publicado: (2023)

Lack of common TCRA and TCRB clonotypes in CD8(+)/TCRαβ(+) T-cell large granular lymphocyte leukemia: a review on the role of antigenic selection in the immunopathogenesis of CD8(+) T-LGL
por: Sandberg, Y, et al.
Publicado: (2014)

Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2021)

Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
por: Brüggemann, Monika, et al.
Publicado: (2019)

A Comprehensive Assessment to Enable Recovery of the Homeless: The HOP-TR Study
por: Van Everdingen, Coline, et al.
Publicado: (2021)

ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia
por: van Outersterp, Inge, et al.
Publicado: (2023)

Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods
por: Kotrová, Michaela, et al.
Publicado: (2022)

Flow cytometric minimal residual disease assessment in B‐cell precursor acute lymphoblastic leukaemia patients treated with CD19‐targeted therapies — a EuroFlow study
por: Verbeek, Martijn W. C., et al.
Publicado: (2021)

Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
por: Knecht, Henrik, et al.
Publicado: (2019)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

High-Throughput, Amplicon-Based Sequencing of the CREBBP Gene as a Tool to Develop a Universal Platform-Independent Assay
por: Fuellgrabe, Marc W., et al.
Publicado: (2015)

Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome
por: Oliveira, Elen, et al.
Publicado: (2022)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

NP-MRD: the Natural Products Magnetic Resonance Database
por: Wishart, David S, et al.
Publicado: (2021)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2023)

P829: GENOMIC PROFILING IN CFDNA COMPLEMENTS MOLECULAR DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA
por: Schilhabel, Anke, et al.
Publicado: (2023)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
por: Shiomi, Daisuke, et al.
Publicado: (2013)

Accident with Tr. Iodi
por: Carmichael, J. C. G.
Publicado: (1879)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
por: van der Linde, Riana, et al.
Publicado: (2023)

PID Comes Full Circle: Applications of V(D)J Recombination Excision Circles in Research, Diagnostics and Newborn Screening of Primary Immunodeficiency Disorders
por: van Zelm, Menno C., et al.
Publicado: (2011)

Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study
por: Böttcher, Sebastian, et al.
Publicado: (2022)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

MRD Tailored Therapy in AML: What We Have Learned So Far
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Technical Report Abstracts: TR-365 to TR-415
Publicado: (1993)

Technical Report Abstracts: TR-335 to TR-364
Publicado: (1993)

Technical Report Abstracts: TR-143 to TR-223
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_j3aenrskbhabs2oacb1qs9fgt0